NEW YORK – Bristol Myers Squibb on Friday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive recommendation for two of its immune checkpoint inhibitors, nivolumab (Opdivo) and ipilimumab (Yervoy), in combination with platinum-based chemotherapy as a first-line treatment for metastatic non-small cell lung cancer patients whose tumors lack EGFR mutations or ALK translocations.
Following CHMP's recommendation, the European Commission will review the opinion and decide whether to approve the regimen.